Jazz Pharmaceuticals Letterhead]Transition and Termination Agreement • November 5th, 2019 • Jazz Pharmaceuticals PLC • Pharmaceutical preparations
This letter contains the Transition and Termination Agreement (the “Agreement”) between you and Jazz Pharmaceuticals, Inc. (the “Company”).
August 31, 1995 Mr. Oliver Roux Francesco Smalto International 29 rue Marbeuf 75008 Paris France Transition and Termination Agreement Dear Mr. Roux, Following up on our meeting in Paris on July 12 and our subsequent telephone conversations, this will...Transition and Termination Agreement • November 13th, 1995 • Parlux Fragrances Inc • Perfumes, cosmetics & other toilet preparations
TRANSITION AND TERMINATION AGREEMENTTransition and Termination Agreement • June 11th, 2010 • International Game Technology • Miscellaneous manufacturing industries
THIS TRANSITION AND TERMINATION AGREEMENT (this "Agreement") is dated as of June 9th, 10 (the "Effective Date") and is by and between the closed company with limited liability under Dutch law IGT—Europe B.V., with corporate seat at Amsterdam and offices at (2131 HC) Hoofddorp, Bijlmermeerstraat 30, (the "Company"), and Mr. Paulus Johannes Cornelis Aloysius Karskens, born on 12 August 1952 at Amsterdam and residing at (3581 SV) Utrecht, Wolter Heukelslaan 70, (the "Executive").
TRANSITION AND TERMINATION AGREEMENTTransition and Termination Agreement • November 5th, 2004 • Insight Communications Co Inc • Cable & other pay television services • Delaware
THIS TRANSITION AND TERMINATION AGREEMENT (this “Agreement”) is made as of this 22nd day of July, 2004, by and between Comcast of Montana/Indiana/Kentucky/Utah (f/k/a InterMedia Partners Southeast), a California general partnership (“Company”), and Insight Communications Company, L.P., a Delaware limited partnership (“Consultant”).
Jazz Pharmaceuticals Letterhead]Transition and Termination Agreement • May 5th, 2020 • Jazz Pharmaceuticals PLC • Pharmaceutical preparations
As discussed, this letter amends the Transition and Termination Agreement (the “Agreement”) between you and Jazz Pharmaceuticals, Inc. (the “Company”) dated October 31, 2019, as set forth below:
